6-Sep-2024 4:19 PM CST - MarketWatch Incyte Corp. stock underperforms Friday when compared to competitors Shares of Incyte Corp. INCY slid 2.70% to $61.26 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.73% to 5,408.42 and Dow Jones Industrial Average DJIA falling 1.
3-Sep-2024 4:19 PM CST - MarketWatch Incyte Corp. stock outperforms competitors on strong trading day Shares of Incyte Corp. INCY inched 0.99% higher to $66.31 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.12% to 5,528.93 and Dow Jones Industrial Average DJIA falling 1.51% to ...
3-Sep-2024 1:16 AM CST - Business Insider RBC Capital Sticks to Their Hold Rating for Incyte (INCY) Citi maintained a Buy rating on Incyte (NASDAQ: INCY). INCY market cap is currently $12.65B and has a P/E ratio of 185.01. Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that ...
22-Aug-2024 4:20 PM CST - MarketWatch Incyte Corp. stock underperforms Thursday when compared to competitors Shares of Incyte Corp. INCY shed 1.76% to $63.02 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.89% to 5,570.64 and Dow Jones Industrial Average DJIA falling 0.43% to 40,712.78.
17-Aug-2024 12:20 AM CST - Zacks Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug Incyte INCY announced that the late-stage inMIND study on tafasitamab met its primary and secondary endpoints. This phase III study is evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody,
6-Sep-2024 4:19 PM CST - MarketWatch Incyte Corp. stock underperforms Friday when compared to competitors Shares of Incyte Corp. INCY slid 2.70% to $61.26 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 1.73% to 5,408.42 and Dow Jones Industrial Average DJIA falling 1.
3-Sep-2024 4:19 PM CST - MarketWatch Incyte Corp. stock outperforms competitors on strong trading day Shares of Incyte Corp. INCY inched 0.99% higher to $66.31 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.12% to 5,528.93 and Dow Jones Industrial Average DJIA falling 1.51% to ...
3-Sep-2024 1:16 AM CST - Business Insider RBC Capital Sticks to Their Hold Rating for Incyte (INCY) Citi maintained a Buy rating on Incyte (NASDAQ: INCY). INCY market cap is currently $12.65B and has a P/E ratio of 185.01. Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that ...
22-Aug-2024 4:20 PM CST - MarketWatch Incyte Corp. stock underperforms Thursday when compared to competitors Shares of Incyte Corp. INCY shed 1.76% to $63.02 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.89% to 5,570.64 and Dow Jones Industrial Average DJIA falling 0.43% to 40,712.78.
17-Aug-2024 12:20 AM CST - Zacks Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug Incyte INCY announced that the late-stage inMIND study on tafasitamab met its primary and secondary endpoints. This phase III study is evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody,
